Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emrusolmin - Modag

Next Previous
Drug Profile

Emrusolmin - Modag

Alternative Names: anle-138b; TEV-56286

Latest Information Update: 15 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ludwig-Maximilians-University; Max Planck Institute for Biophysical Chemistry
  • Developer Modag; Nottingham Trent University; Teva Pharmaceutical Industries
  • Class Antidementias; Antiparkinsonians; Dioxoles; Pyrazoles; Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Protein aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple system atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple system atrophy
  • Phase I Unspecified
  • No development reported Alzheimer's disease; Creutzfeldt-Jakob disease; Parkinson's disease

Most Recent Events

  • 09 Sep 2025 Emrusolmin - Modag receives Fast Track designation for Multiple system atrophy [PO,Capsule] in USA
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Parkinson's-disease in United Kingdom (PO)
  • 02 Jun 2025 Teva Pharmaceutical completes a phase I bioavailability trial in Healthy volunteers in USA (PO) (NCT06911567)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top